Literature DB >> 32042676

Treatment optimization and prognostic considerations for primary squamous cell carcinoma of the thyroid.

Wenlong Wang1, Qianhui Ouyang1, Chaoyang Meng1, Lanyu Jing1, Xinying Li1.   

Abstract

BACKGROUND: Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare aggressive malignancy that usually presents in an advanced stage and has a poor prognosis. Our study aimed to investigate the clinical characteristics, treatment, and prognosis of PSCCT.
METHODS: We retrospectively reviewed the medical information of patients with PSCCT diagnosed from January 2006 to May 2018 at Xiangya Hospital. Survival analysis was conducted using the Kaplan-Meier method, and Log-Rank tests were performed for statistical testing.
RESULTS: We identified 12 patients with PSCCT (nine males and three females), accounting for only 0.19% of all thyroid cancer diagnosed during this time period. The median age of these patients was 59.5 years old and their symptoms included neck masses (n=5), hoarseness (n=2), dyspnea (n=1), dysphagia (n=1) and neck pain (n=1). Four patients were in stage IVA, five were stage IVB, and three patients were stage IVC. Six patients underwent comprehensive treatment (surgery + radiotherapy or surgery + radiotherapy + chemotherapy) and the remaining patients received radiotherapy and/or chemotherapy. The 6-month survival rate was 66.7%, compared to a 1-year survival rate of 25.0%, with a median overall survival time was 10.5 months. Kaplan-Meier analysis showed that the comprehensive treatment was superior to radiotherapy and/or chemotherapy (P=0.003).
CONCLUSIONS: PSCCT is a rare type of thyroid cancer that is highly invasive and has a poor prognosis. We show that a comprehensive treatment plan can significantly improve patient survival. 2019 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Squamous cell carcinoma; chemotherapy; radiotherapy; thyroid

Year:  2019        PMID: 32042676      PMCID: PMC6989903          DOI: 10.21037/gs.2019.11.07

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  23 in total

1.  The treatment and outcome analysis of primary squamous cell carcinoma of the thyroid.

Authors:  Ryuji Yasumatsu; Masanobu Sato; Ryutaro Uchi; Takafumi Nakano; Kazuki Hashimoto; Ryunosuke Kogo; Masahiko Taura; Mioko Matsuo; Torahiko Nakashima; Takashi Nakagawa
Journal:  Auris Nasus Larynx       Date:  2017-07-22       Impact factor: 1.863

2.  Prediction of permanent hypoparathyroidism by parathyroid hormone and serum calcium 24 h after thyroidectomy.

Authors:  Wenlong Wang; Fada Xia; Chaoyang Meng; Zhejia Zhang; Ning Bai; Xinying Li
Journal:  Am J Otolaryngol       Date:  2018-09-03       Impact factor: 1.808

3.  Primary Squamous Cell Carcinoma in the Thyroid Gland: A Population-Based Analysis Using the SEER Database.

Authors:  Shuwen Yang; Cunfu Li; Xiao Shi; Ben Ma; Weibo Xu; Hongyi Jiang; Wanlin Liu; Qinghai Ji; Yu Wang
Journal:  World J Surg       Date:  2019-05       Impact factor: 3.352

4.  Squamous differentiation in papillary thyroid carcinoma: a rare feature of aggressive disease.

Authors:  Toni Beninato; Wouter P Kluijfhout; Frederick Thurston Drake; Elham Khanafshar; Jessica E Gosnell; Wen T Shen; Quan-Yang Duh; Insoo Suh
Journal:  J Surg Res       Date:  2017-11-09       Impact factor: 2.192

5.  Primary squamous-cell thyroid carcinoma - a successful treatment with five-year follow-up.

Authors:  Andrzej Wygoda; Tomasz Rutkowski; Bogna Szcześniak-Kłusek; Jolanta Mrochem-Kwarciak; Maja Jędrzejewska; Krzysztof Składowski
Journal:  Endokrynol Pol       Date:  2017-09-07       Impact factor: 1.582

6.  Squamous cell carcinoma of the thyroid: an aggressive tumor associated with tall cell variant of papillary thyroid carcinoma.

Authors:  C G Kleer; T J Giordano; M J Merino
Journal:  Mod Pathol       Date:  2000-07       Impact factor: 7.842

Review 7.  Squamous cell carcinoma of the thyroid gland: primary or secondary disease?

Authors:  M I Syed; M Stewart; S Syed; S Dahill; C Adams; D R McLellan; L J Clark
Journal:  J Laryngol Otol       Date:  2010-10-18       Impact factor: 1.469

8.  Primary squamous cell carcinoma of the thyroid on FDG PET/CT.

Authors:  Liang Cai; Yue Chen; Zhanwen Huang; Jingbo Wu
Journal:  Clin Nucl Med       Date:  2014-11       Impact factor: 7.794

9.  Primary squamous cell carcinoma of the thyroid: Case report and systematic review of the literature.

Authors:  Florian Struller; Moritz Senne; Claudius Falch; Andreas Kirschniak; Alfred Konigsrainer; Sven Muller
Journal:  Int J Surg Case Rep       Date:  2017-06-13

10.  Immunohistochemical Features of Primary Pure Squamous Cell Carcinoma in the Thyroid: An Autopsy Case.

Authors:  Satoshi Koyama; Kazunori Fujiwara; Kanae Nosaka; Takahiro Fukuhara; Tsuyoshi Morisaki; Naritomo Miyake; Hiroya Kitano; Hiromi Takeuchi
Journal:  Case Rep Oncol       Date:  2018-06-28
View more
  5 in total

1.  The influence of nodule size on the aggressiveness of thyroid carcinoma varies with patient's age.

Authors:  Chaoyang Meng; Wenlong Wang; Yuezhong Zhang; Xinying Li
Journal:  Gland Surg       Date:  2021-03

2.  Primary and metastatic squamous cell carcinoma of the thyroid gland: Two case reports.

Authors:  Xing Zhao; Pengyu Hao; Jiangbei Tian; Jirun Sun; Dawei Chen; Zhehui Cui; Libo Xin; Yanmin Song; Gang Zhang
Journal:  Open Life Sci       Date:  2022-09-16       Impact factor: 1.311

3.  Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report.

Authors:  Meng-Lun Hsieh; Brian M Besch; Jo Elle G Peterson; Christina Henson
Journal:  J Med Case Rep       Date:  2022-10-05

4.  A Primary Squamous Cell Carcinoma of the Thyroid Presenting as the Anaplastic Thyroid Carcinoma: A Case Report.

Authors:  Rui-Zhe Zheng; Guo-Hui Huang; Ying-Jie Xu
Journal:  Front Surg       Date:  2020-10-19

5.  Contrast-Enhanced Ultrasound of Primary Squamous Cell Carcinoma of the Thyroid: A Case Report.

Authors:  Sijie Chen; Qinghai Peng; Qi Zhang; Chengcheng Niu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-11       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.